Business Description
Jenburkt Pharmaceuticals Ltd
ISIN : INE354A01013
Compare
Compare
Traded in other countries / regions
524731.India IPO Date
2000-11-27Description
Jenburkt Pharmaceuticals Ltd is engaged in the manufacturing, producing, developing, and marketing of pharmaceutical formulations. The company operates in one segment - pharmaceutical formulations. The company generates key revenue from the local market.
Financial Strength
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 36.94 | |||||
| Equity-to-Asset | 0.87 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | 0.05 | |||||
| Interest Coverage | 110.95 | |||||
| Piotroski F-Score | 8/9 | |||||
| Altman Z-Score | 14.74 | |||||
| Beneish M-Score | -1.98 | |||||
| WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.6 | |||||
| 3-Year EBITDA Growth Rate | 17.7 | |||||
| 3-Year EPS without NRI Growth Rate | 17.7 | |||||
| 3-Year FCF Growth Rate | -31.9 | |||||
| 3-Year Book Growth Rate | 15.2 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 61.1 | |||||
| 9-Day RSI | 60.06 | |||||
| 14-Day RSI | 59.09 | |||||
| 6-1 Month Momentum % | 23.84 | |||||
| 12-1 Month Momentum % | 49.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.89 | |||||
| Quick Ratio | 5.38 | |||||
| Cash Ratio | 4.41 | |||||
| Days Inventory | 106.96 | |||||
| Days Sales Outstanding | 40.82 | |||||
| Days Payable | 75.6 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.24 | |||||
| Dividend Payout Ratio | 0.22 | |||||
| Forward Dividend Yield % | 1.24 | |||||
| 5-Year Yield-on-Cost % | 1.24 | |||||
| 3-Year Average Share Buyback Ratio | 1.3 | |||||
| Shareholder Yield % | 1.18 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 79.07 | |||||
| Operating Margin % | 23.9 | |||||
| Net Margin % | 20.49 | |||||
| FCF Margin % | 3.77 | |||||
| ROE % | 20.99 | |||||
| ROA % | 18.31 | |||||
| ROIC % | 30.51 | |||||
| ROC (Joel Greenblatt) % | 128.96 | |||||
| ROCE % | 27.62 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 17.93 | |||||
| PE Ratio without NRI | 17.93 | |||||
| Shiller PE Ratio | 22.15 | |||||
| Price-to-Owner-Earnings | 28.04 | |||||
| PEG Ratio | 1.93 | |||||
| PS Ratio | 3.68 | |||||
| PB Ratio | 3.44 | |||||
| Price-to-Tangible-Book | 3.45 | |||||
| Price-to-Free-Cash-Flow | 97.55 | |||||
| Price-to-Operating-Cash-Flow | 66.89 | |||||
| EV-to-EBIT | 11.38 | |||||
| EV-to-EBITDA | 10.76 | |||||
| EV-to-Revenue | 3.17 | |||||
| EV-to-FCF | 75.83 | |||||
| Price-to-Projected-FCF | 2.3 | |||||
| Price-to-DCF (Earnings Based) | 1.14 | |||||
| Price-to-DCF (FCF Based) | 9.8 | |||||
| Price-to-Median-PS-Value | 1.71 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.45 | |||||
| Price-to-Graham-Number | 1.66 | |||||
| Price-to-Net-Current-Asset-Value | 6.75 | |||||
| Price-to-Net-Cash | 9.99 | |||||
| Earnings Yield (Greenblatt) % | 8.79 | |||||
| FCF Yield % | 1.02 | |||||
| Forward Rate of Return (Yacktman) % | 11.42 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Jenburkt Pharmaceuticals Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ₹) | 1,479.203 | ||
| EPS (TTM) (₹) | 68.66 | ||
| Beta | 1.22 | ||
| Volatility % | 42.9 | ||
| 14-Day RSI | 59.09 | ||
| 14-Day ATR (₹) | 75.559336 | ||
| 20-Day SMA (₹) | 1157.47 | ||
| 12-1 Month Momentum % | 49.88 | ||
| 52-Week Range (₹) | 643.2 - 1375 | ||
| Shares Outstanding (Mil) | 4.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 8 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Jenburkt Pharmaceuticals Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Jenburkt Pharmaceuticals Ltd Stock Events
| Event | Date | Price(₹) | ||
|---|---|---|---|---|
| No Event Data | ||||
Jenburkt Pharmaceuticals Ltd Frequently Asked Questions
What is Jenburkt Pharmaceuticals Ltd(BOM:524731)'s stock price today?
The current price of BOM:524731 is ₹1231.30. The 52 week high of BOM:524731 is ₹1375.00 and 52 week low is ₹643.20.
When is next earnings date of Jenburkt Pharmaceuticals Ltd(BOM:524731)?
The next earnings date of Jenburkt Pharmaceuticals Ltd(BOM:524731) is .
Does Jenburkt Pharmaceuticals Ltd(BOM:524731) pay dividends? If so, how much?
The Dividend Yield %  of Jenburkt Pharmaceuticals Ltd(BOM:524731) is 1.24% (As of Today), Highest Dividend Payout Ratio of Jenburkt Pharmaceuticals Ltd(BOM:524731) was 0.57. The lowest was 0.03. And the median was 0.25. The  Forward Dividend Yield % of Jenburkt Pharmaceuticals Ltd(BOM:524731) is 1.24%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers